3-way drug deal benefits all: GlaxoSmithkline CEO
April 22, 2014 at 07:25 AM EDT
The three-way deal with pharma giant Novartis allows GlaxoSmithKline to "significantly expand" its world-leading vaccine business and create value for shareholders, GSK CEO Sir Andrew Witty says.
